ArticleJournal of biochemistry2026
Characterization of p16-positive stromal cells in age-related cardiac disorders.
Article in Journal of biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The heart undergoes structural alterations, including fibrosis and cardiomyocyte hypertrophy with age. These alterations are accompanied by functional decline, resulting in heart failure. Although cardiac stromal cells such as fibroblasts and macrophages are known to play a role in age-related cardiac changes, specific subsets of these cells may have a more pronounced effect on the development of these alterations. In this study, we analyzed p16, a marker of senescence,-positive (p16+) cells in cardiac fibrosis by single-cell RNA sequencing of aged p16-Tom mice, in which p16+ cells can be labelled in the presence of tamoxifen. We found that TGF-β signalling were significantly enriched in the transcriptome of p16+ fibroblasts compared with p16- fibroblasts. Besides, BMP4 was upregulated in p16+ fibroblasts. This activation potentially promoted the expression of collagen genes such as Col4a1 and Col5a3. Selective elimination of p16+ fibroblasts ameliorated cardiac fibrosis in aged p16-Col1a2-LRTD mice, with levels comparable to those observed in young mice. These findings suggest that p16+ fibroblasts play a critical role in age-associated cardiac fibrosis. We further demonstrate the potential use of transcriptomic signatures of p16+ fibroblasts to identify human fibroblast subsets causing age-related cardiac diseases such as dilated cardiomyopathy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.